Unibios
Unibios (BIOSK) closed at €2.06 on 09/11/2026, -0.24% on the day. Market cap €35.9m, P/E 24.0.
Announcements to the exchange
BIOSK −20.3% (€2.585 → €2.06) · General Index —
Deepest fall inside it: −30.4% (17 Aug → 29 Oct 2026)
Drag across the chart to measure any stretchSlide sideways across the chart to measure
Key statistics
12 months to Jun 2026 unless a figure says otherwise
Profile
At the 9 Nov close- Market value
- Enterprise valueJun 2026est.
- Shares outstandingJun 2026
- Revenue12 months to Jun 2026
- Employees
- Free floatest.
- Traded a day, 3-month average
Valuation
12 months to Jun 2026- P/EFY2025
- P/B
- EV/Salesest.
- EV/EBITDAest.
- P/FCF
- —
- Dividend yield
5 years, on reported full years: 7.3–21.5×, median 14.0×. Today 13.5×, lower than 52% of months.
not meaningful here
Margins
12 months to Jun 2026- GrossFY2025
- EBITDA
- Operating (EBIT)
- Pre-tax
- Net
- Free cash flow
Net margin = the shareholders' profit ÷ group revenue.
Returns
12 months to Jun 2026- ROE
- ROCE
- ROICest.
- ROAFY2025
- ROE, 5-year averageFY2021–25
- Tax rateFY2025
Financial health
Jun 2026- CashDec 2025
- Net debt
- Net debt ÷ EBITDA
- Debt ÷ equityDec 2025
- Interest cover12 months to Jun 2026
leases included
Growth
- Revenue, last yearFY2025
- Revenue, last halfH1 2026
- EPS, last yearFY2025
- Revenue, 3 yearsFY2022–25, a year
- Revenue, 5 yearsFY2020–25, a year
- EPS, 3 yearsFY2022–25, a year
- Shares, 3 yearsFY2022–25
Dividends
FY2025- Yield, last 12 months
- Per share
- Payout
- Covered by free cash flow
- —
- Years paid, last fiveFY2021–25
not meaningful here
Trading and risk
From our closes, dividends reinvested- Total return, 1 year
- −33.5%
- 3 years, a year
- +23.1%
- 5 years, a year
- +27.6%
- 10 years, a year
- +13.4%
- Volatility, 1 year
- 34.9%
- Beta to the General Index
- 0.67×
- Deepest fall, 1 year / 5 years
- −35.2% / −36.6%
- 52-week range
- €2.015–€3.11
Where the figures come from: the company's reports, reviewed by us · annual accounts filed in ESEF format · results announcements on the exchange · our own closing prices. No forecasts or target prices are stored.
Financial charts
From the stored figures: the reviewed dossier first, then the annual reports (ESEF) and results announcements
Loading the charts…
Valuation
2 companies| Metric | BIOSK | Peer median | Peer range |
|---|---|---|---|
| P/E | 24.0 | — | |
| P/B | 1.8 | 2.8 | 1.6 3.9 |
| P/S | 2.37 | 0.98 | 0.38 1.57 |
| EV/EBITDA | 29.5 | 11.3 | 9.0 13.6 |
| Dividend yield | 0.0% | 2.0% | 0.0% 4.1% |
| Payout ratio | 0.0% | 13.0% | 0.0% 26.0% |
| Gross margin | 42.5% | — | |
| Operating margin | 5.1% | — | |
| Net margin | 2.6% | — | |
| ROE | 2.0% | — | |
| Revenue growth (last full year) | −5.6% | 20.8% | 19.6% 22.1% |
| Net debt | €7.0m | €3.2m | -€5.4m €11.7m |
Peers: Machinery & equipment
The company
AI-draftedUnibios is a holding company focused on water treatment through Watera. The group manufactures and installs treatment and desalination systems and supplies technical services to industrial customers, municipalities, hotels and hospitals, mainly in Greece. It also controls French Watera, formerly Osmosun, which supplies solar-powered desalination technology.
- Oct 2026The €0.025-per-share capital return was rescheduled: ex-date 10 December and payment on 17 December 2026.10
- Sep 2026H1 2026: sales rose 19.9% to €7.669m, owners earned €0.120m (group loss €0.139m) and cash fell to €1.163m.8,9
- Sep 2026Shareholders approved Watera International’s merger into French Watera; it is expected to take effect before the end of 2026, with Unibios projected to hold 87%.2,6,11
- Sep 2026The AGM approved a €0.025-per-share capital return and buyback authority for 2027–2028.7
- Apr 2026323,887 new BIOSK shares from the December 2025 private placement began trading; part of the proceeds funded the €0.400m purchase of Lytrasco in March.5,8
- Jul 2025The investment giving Unibios 65% of Osmosun, subsequently renamed Watera, completed.1,3
- Greece generated 76.7% of H1 2026 revenue and foreign markets 23.3%.8
- Operating cash flow was −€2.514m in H1 2026 and calculated net financial debt rose to €6.990m.8
- The 2025 purchase of 65% of Osmosun combined €1.610m cash with contributed Watera International shares.1,3
- The AGM approved a €0.025-per-share capital return, with ex-date on 10 December and payment on 17 December 2026; it is not a regular dividend.7,10
- The merger of Watera International into Watera SA is expected to take effect before the end of 2026, leaving Unibios with about 87%.6,11
- 1.FY2025 audited annual reportUnibios Holdings S.A. · 30/04/2026official
- 2.Watera September 2026 merger presentationWatera S.A. · 15/09/2026official
- 3.Watera S.A. FY2025 annual report — entity and transaction detailsWatera S.A. · 30/04/2026official
- 4.Current XATH instrument recordESMAofficial
- 5.Issuer regulatory announcements archive 2026 and earlierUnibios Holdings S.A.official
- 6.Approval of Watera cross-border merger by both shareholder meetingsWatera S.A. via Actusnews · 16/09/2026official
- 7.Decisions of the 9 September 2026 AGMUnibios Holdings S.A. / Euronext Athens · 09/09/2026official
- 8.H1 2026 interim reportUnibios Holdings S.A. · 30/09/2026official
- 9.H1 2026 financial results press releaseUnibios Holdings S.A. via Euronext Athens · 30/09/2026official
- 10.Modification of the 2026 financial calendar (capital-return dates)Unibios Holdings S.A. via Euronext Athens · 02/10/2026official
- 11.Watera S.A. H1 2026 half-year financial reportWatera S.A. · 30/09/2026official